In a recent study led by Danielle A Bischof, MD of Johns Hopkins and published in JAMA Surgery, the authors propose a new way of estimating disease-free survival for GIST patients – Conditional Disease-free Survival [...]
A recent roundtable discussion at the National Comprehensive Cancer Network’s (NCCN) 20th Annual Conference opened up a discussion on treatment costs and introduced the proposed use of evidence blocks to compare treatments. Currently, the [...]
In addition to spending time catching up with fellow patients and caregivers and attending the myriad of useful workshops featured at Life Fest 2014, participants were treated to an update of what is new in [...]
The LRG is proud to announce that the inaugural class of our GIST Expert Patient Training Program has been completed. The class, which was open to GIST patients, caregivers, and other members oaf the extended GIST community, was comprised of just under 20 students and was a comprehensive offering designed to help participants better understand the science behind GIST.
The Life Raft Group is pleased to announce the release of the first issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to GIST.
The Life Raft Group is pleased to formally announce the creation of its first ever Global Medical Team. This team, which consists of leading physicians throughout the world, will provide the LRG the opportunity to [...]
From October 30th to November 2nd the Life Raft Group staff members attended the annual Connective Tissue Oncology Society (CTOS) Meeting in NYC.
The LRG Research Team recently held a teleconference that focused primarily on a study the team will collaborate on and intends to publish.
Drs. Jonathan Fletcher, of Brigham & Women’s Hospital, Harvard University and Maria Debiec-Rychter, of the Catholic University in Leuven, Belgium, members of the LRG Research Team were part of a recently published study that looked at the effectiveness of GDC-0941, a PI3K inhibitor when used in combination with imatinib (Gleevec).
Sutent is the second-line approved treatment for Gastrointestinal Stromal Tumor and is prescribed when treatment with the first-line drug, Gleevec (Imatinib) is no longer effective or cannot be tolerated. The two drugs work differently, so [...]